

Marco Tucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9100202/publications.pdf>

Version: 2024-02-01

104
papers

8,813
citations

101543

36
h-index

45317

90
g-index

104
all docs

104
docs citations

104
times ranked

19498
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879463.	3.2	317
3	Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: Role of interleukin-18. Arthritis and Rheumatism, 2008, 58, 251-262.	6.7	207
4	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget, 2017, 8, 106132-106142.	1.8	174
5	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Annals of Oncology, 2014, 25, 1404-1410.	1.2	133
6	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
7	Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis and Rheumatism, 2004, 50, 1842-1849.	6.7	120
8	Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clinical and Experimental Immunology, 2004, 138, 171-178.	2.6	110
9	Negative regulation of erythroblast maturation by Fas-L+/TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood, 2002, 99, 1305-1313.	1.4	97
10	Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clinical and Experimental Immunology, 2008, 154, 247-254.	2.6	97
11	Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. Oncotarget, 2018, 9, 20826-20837.	1.8	97
12	Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. Aids, 1996, 10, 131-141.	2.2	94
13	Urinary biomarkers in lupus nephritis. Autoimmunity Reviews, 2006, 5, 383-388.	5.8	90
14	Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. Frontiers in Oncology, 2019, 9, 1148.	2.8	90
15	The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology, 2019, 109, 83-99.	2.5	87
16	Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications. Cancer Treatment Reviews, 2015, 41, 798-808.	7.7	85
17	Non-Melanoma Skin Cancers: Biological and Clinical Features. International Journal of Molecular Sciences, 2020, 21, 5394.	4.1	83
18	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer, 2021, 142, 18-28.	2.8	81

#	ARTICLE	IF	CITATIONS
19	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. <i>Onc Immunology</i> , 2018, 7, e1387706.	4.6	76
20	Induction of Apoptosis by the Hydrocarbon Oil Pristane: Implications for Pristane-Induced Lupus. <i>Journal of Immunology</i> , 2005, 175, 4777-4782.	0.8	67
21	Th1 cytokines in the pathogenesis of lupus nephritis: The role of IL-18. <i>Autoimmunity Reviews</i> , 2005, 4, 542-548.	5.8	66
22	Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. <i>British Journal of Haematology</i> , 2003, 122, 39-52.	2.5	65
23	Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. <i>Clinical and Experimental Immunology</i> , 2006, 146, 21-31.	2.6	59
24	The immune escape in melanoma: role of the impaired dendritic cell function. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1395-1404.	3.0	56
25	PTHrP Produced by Myeloma Plasma Cells Regulates Their Survival and Pro-Osteoclast Activity For Bone Disease Progression. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 55-66.	2.8	53
26	Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. <i>Blood</i> , 2001, 97, 1155-1164.	1.4	51
27	Cytokine Overproduction, T-Cell Activation, and Defective T-Regulatory Functions Promote Nephritis in Systemic Lupus Erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-6.	3.0	51
28	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
29	Antiphosphatidylserine antibodies in human immunodeficiency virus-1 patients with evidence of T-cell apoptosis and mediate antibody- dependent cellular cytotoxicity [see comments]. <i>Blood</i> , 1996, 87, 5185-5195.	1.4	46
30	In vitro anti- α myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. <i>British Journal of Haematology</i> , 2012, 157, 586-598.	2.5	46
31	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	2.8	45
32	The Interplay of Chemokines and Dendritic Cells in the Pathogenesis of Lupus Nephritis. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 421-432.	3.8	43
33	Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation. <i>British Journal of Haematology</i> , 2013, 161, 821-831.	2.5	42
34	Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia. <i>Journal of Hypertension</i> , 2006, 24, 1307-1318.	0.5	41
35	Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis. <i>Journal of Translational Medicine</i> , 2019, 17, 230.	4.4	41
36	Does cilengitide deserve another chance?. <i>Lancet Oncology</i> , The, 2014, 15, e584-e585.	10.7	40

#	ARTICLE	IF	CITATIONS
37	miRNAs in melanoma: a defined role in tumor progression and metastasis. Expert Review of Clinical Immunology, 2016, 12, 79-89.	3.0	40
38	Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clinical and Experimental Medicine, 2019, 19, 1-21.	3.6	39
39	Dendritic Cells and Malignant Plasma Cells: An Alliance in Multiple Myeloma Tumor Progression?. Oncologist, 2011, 16, 1040-1048.	3.7	38
40	Av β 3 integrin: Pathogenetic role in osteotropic tumors. Critical Reviews in Oncology/Hematology, 2015, 96, 183-193.	4.4	38
41	Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression. International Journal of Molecular Sciences, 2020, 21, 52.	4.1	38
42	Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now?. Frontiers in Oncology, 2019, 9, 521.	2.8	35
43	SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. Oncotarget, 2018, 9, 25355-25382.	1.8	34
44	Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro. Experimental Hematology, 2011, 39, 773-783.e1.	0.4	33
45	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2014, 9, e105268.	2.5	33
46	β 3 Integrin Subunit Mediates the Bone-Resorbing Function Exerted by Cultured Myeloma Plasma Cells. Cancer Research, 2009, 69, 6738-6746.	0.9	32
47	Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-I) in active lupus. Lupus, 2003, 12, 8-14.	1.6	31
48	Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. Cancer Treatment Reviews, 2018, 69, 21-28.	7.7	31
49	Oversecretion of Cytokines and Chemokines in Lupus Nephritis Is Regulated by Intraparenchymal Dendritic Cells. Annals of the New York Academy of Sciences, 2009, 1173, 449-457.	3.8	29
50	The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine. Tumor Biology, 2019, 41, 101042831983713.	1.8	29
51	The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. Genes, 2021, 12, 727.	2.4	29
52	Increased IL-18 Production by Dendritic Cells in Active Inflammatory Myopathies. Annals of the New York Academy of Sciences, 2007, 1107, 184-192.	3.8	26
53	Bone-Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?. Oncologist, 2009, 14, 264-275.	3.7	26
54	Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. Clinical Sarcoma Research, 2013, 3, 6.	2.3	22

#	ARTICLE	IF	CITATIONS
55	Recent Advances in Understanding the Pathogenesis of Anemia in Multiple Myeloma. <i>International Journal of Hematology</i> , 2003, 78, 121-125.	1.6	21
56	A Peculiar Molecular Profile of Umbilical Cord-Mesenchymal Stromal Cells Drives Their Inhibitory Effects on Multiple Myeloma Cell Growth and Tumor Progression. <i>Stem Cells and Development</i> , 2015, 24, 1457-1470.	2.1	21
57	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987554.	3.2	21
58	A Lipidomic Approach to Identify Potential Biomarkers in Exosomes From Melanoma Cells With Different Metastatic Potential. <i>Frontiers in Physiology</i> , 2021, 12, 748895.	2.8	21
59	Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations. <i>BMC Cancer</i> , 2016, 16, 87.	2.6	20
60	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. <i>Cancers</i> , 2021, 13, 475.	3.7	20
61	Sjögren's syndrome: an autoimmune disorder with otolaryngological involvement. <i>Acta Otorhinolaryngologica Italica</i> , 2005, 25, 139-44.	1.5	19
62	Role of Active Drug Transporters in Refractory Multiple Myeloma. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 218-224.	2.1	18
63	Large Extracellular Vesicles—A New Frontier of Liquid Biopsy in Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6543.	4.1	17
64	Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. <i>BMC Cancer</i> , 2015, 15, 692.	2.6	16
65	Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer. <i>Scientific Reports</i> , 2019, 9, 17276.	3.3	16
66	The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 505-519.	2.6	14
67	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021, 19, 270.	4.4	14
68	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	6.3	14
69	An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. <i>Experimental Hematology</i> , 2014, 42, 897-908.e1.	0.4	13
70	Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice. <i>Neuroendocrinology</i> , 2021, 111, 207-216.	2.5	13
71	Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview. <i>Cancers</i> , 2021, 13, 2114.	3.7	12
72	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. <i>Journal of Translational Medicine</i> , 2022, 20, 159.	4.4	12

#	ARTICLE	IF	CITATIONS
73	Functional Fas-ligand expression on T cells from HIV-1-infected patients is unrelated to CD4+ lymphopenia. International Journal of Clinical and Laboratory Research, 1998, 28, 215-225.	1.0	11
74	Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 3022.	4.1	11
75	The Day after Mass COVID-19 Vaccination: Higher Hypermetabolic Lymphadenopathy Detection on PET/CT and Impact on Oncologic Patients Management. Cancers, 2021, 13, 4340.	3.7	11
76	DLC-1 down-regulation via exosomal miR-106b-3p exchange promotes CRC metastasis by the epithelial-to-mesenchymal transition. Clinical Science, 2020, 134, 955-959.	4.3	11
77	Anemia in Multiple Myeloma: Role of Deregulated Plasma Cell Apoptosis. Leukemia and Lymphoma, 2002, 43, 1527-1533.	1.3	10
78	Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells. British Journal of Haematology, 2016, 173, 59-69.	2.5	10
79	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. Frontiers in Oncology, 2020, 10, 1652.	2.8	10
80	Dual-procedural separation of CTCs in cutaneous melanoma provides useful information for both molecular diagnosis and prognosis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090541.	3.2	10
81	Immunomodulation of T and B cell functions in multiple myeloma patients treated with combined erythropoietin and \pm -interferon therapy. International Journal of Clinical and Laboratory Research, 1995, 25, 79-83.	1.0	9
82	Serum elevations of soluble Fas (CD95/apo-I) concur in deregulating T cell apoptosis during active lupus disease. Clinical and Experimental Medicine, 2002, 2, 13-27.	3.6	9
83	Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanoma. Clinical and Translational Oncology, 2019, 21, 845-854.	2.4	9
84	Primary Soft Tissue Sarcoma of the Heart: An Emerging Chapter in Cardio-Oncology. Biomedicines, 2021, 9, 774.	3.2	9
85	VEINCTR-N, an Immunogenic Epitope of Fas (CD95/Apo-I), and Soluble Fas Enhance T-cell Apoptosis in vitro. II. Functional Analysis and Possible Implications in HIV-1 Disease. Molecular Medicine, 2000, 6, 509-526.	4.4	8
86	The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. Current Treatment Options in Oncology, 2019, 20, 72.	3.0	7
87	Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 581130.	2.8	7
88	Successful treatment with apremilast of severe psoriasis exacerbation during nivolumab therapy for metastatic melanoma. Dermatologic Therapy, 2021, 34, e14653.	1.7	6
89	Immune Disregulation in Cutaneous Squamous Cell Carcinoma of Patients with Recessive Dystrophic Epidermolysis Bullosa: A Single Pilot Study. Life, 2022, 12, 213.	2.4	6
90	Circulating tumor cells from melanoma patients show phenotypic plasticity and metastatic potential in xenograft NOD.CB17 mice. BMC Cancer, 2022, 22, .	2.6	6

#	ARTICLE	IF	CITATIONS
91	Nef protein induces differential effects in CD8+cells from HIV-1-infected patients. European Journal of Clinical Investigation, 1999, 29, 980-991.	3.4	5
92	Paraneoplastic Focal Segmental Glomerulosclerosis in Sarcomatoid Renal Cell Cancer. Journal of Clinical Oncology, 2015, 33, e66-e70.	1.6	5
93	Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma. Human Vaccines and Immunotherapeutics, 2021, , 1-9.	3.3	5
94	Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). Targeted Oncology, 2021, 16, 789-799.	3.6	5
95	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110534.	3.2	5
96	Cytotherapies in multiple myeloma: a complementary approach to current treatments?. Expert Opinion on Biological Therapy, 2013, 13, S23-S34.	3.1	4
97	Everolimus restrains the IL-17A-dependent osteoclast-like transdifferentiation of dendritic cells in multiple myeloma. Experimental Hematology, 2017, 47, 48-53.	0.4	3
98	Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. Journal of Translational Medicine, 2015, 13, .	4.4	2
99	Animal-type melanoma: dog or wolf? A review of the literature and a case report. Expert Reviews in Molecular Medicine, 2018, 20, e5.	3.9	2
100	Primary intimal sarcoma of the thoracic aorta. Journal of Experimental and Clinical Cancer Research, 2005, 24, 139-42.	0.4	2
101	Vascular and Cardiac Prognostic Determinants in Patients with Gynecological Cancers: A Six-Year Follow-up Study. Applied Sciences (Switzerland), 2021, 11, 6091.	2.5	1
102	AlphaV Beta3 (Î±vÎ²3) Integrin Drives the Osteoclastogenesis through a Osteoclast-Like Functional Differentiation of Myeloma Cells.. Blood, 2007, 110, 814-814.	1.4	1
103	Circulating dendritic cell levels identify high-risk stage II-III melanoma patients: a potential role as additional prognostic marker. Journal of Translational Medicine, 2015, 13, .	4.4	0
104	Papillary Meningioma: Case Presentation with Emphasis on Surgical and Medical Therapy of a Rare Variant of Meningioma. Diseases (Basel, Switzerland), 2021, 9, 63.	2.5	0